Solarvest Bioenergy Inc. Granted Organic Omega-3 Patent in Japan

Solarvest Bioenergy Inc. Granted Organic Omega-3 Patent in Japan

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), ("Solarvest" or the "Company"), announces that it has been granted a patent in Japan.  The intellectual property protection concentrates on the production of algal biomass, algal cell cultures, lipid compounds, and compositions thereof, including fatty acids, carotenoids, and fat-soluble vitamins.  This patent adds additional strength to the Company's existing patent portfolio as it commercializes its line of organic Omega-3 products

According to the Principal Company survey "According to the survey, 35.1% of Japanese consumers "currently use" supplements. This is higher among women and the elderly population, with about 45% of women above 50 using supplements.  The professional community in Asia is starting to take many of these products to help with weight management and nutritional deficiencies that come with their less active lifestyles."

"The marketplace is begging for nutritional supplements that meet the needs of these people. Companies like GNC and Nature Made are just starting to tap the Far East Asian market and bring products such as probiotics, multivitamins, DHA, and fish oil".*

After its initial product launch and further industry discussions, the Company has focused on supplying unique "clean label" products to satisfy the demand for premium plant-based, organic Omega-3 health products.  In addition, the Company's wholly-owned subsidiary Eversea has accelerated efforts to offer organic marketing companies and organic-oriented retailers house-branded products (often termed "white label") based on our unique bioavailable Omega-3 ingredient. Channel marketing feedback indicates that there is extensive market demand for the product's unique characteristics, particularly among consumers focused on organic and vegan diets.  The Company's patented Omega-3 active ingredient has obtained FDA NDI (New Dietary Ingredient) certification and is USDA and EU Organic Certified.

AboutSolarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The Company has successfully developed, patented, and produced the world's only plant-based organic certified Omega-3 to satisfy the substantial demand for this essential nutrient.  The Company has also initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Gerri Greenham, Chief Executive Officer

Phone: (647) 204-4095

Email: invest@solarvest.ca

Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the terms of the Offering, the completion of the Offering, and the expected use of the net proceeds received by the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause the actual results, level of activity, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; and regulatory risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement. The Company does not undertake to update any forward-looking information, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

None of the securities of Solarvest have been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or " U.S. persons " (as such term is defined in Regulation S under the U.S. Securities Act) absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy in the United States nor shall there be any sale of the securities in any State in which such offer, solicitation, or sale would be unlawful.

* Breaking into the Health Food and Supplement Market in Japan (principle-c.com)

Copyright (c) 2022 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

SVS:CA
The Conversation (0)
Solarvest BioEnergy Inc.'s Eversea Division Signs Agreement with E3live

Solarvest BioEnergy Inc.'s Eversea Division Signs Agreement with E3live

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), ("Solarvest" or the "Company"), is pleased to announce that its wholly-owned division Eversea America Inc. ("Eversea") has signed an agreement with E3Live, one of the organic industry's premier superfood brands. E3Live has agreed to introduce and market Eversea's organic omega-3 DHA products to its customer base

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest To Sell on China's E-Commerce Application Redbook

Solarvest To Sell on China's E-Commerce Application Redbook

(TheNewswire)

Solarvest BioEnergy Inc.

Solarvest ( TSXV:SVS ) is pleased to announce that the Eversea TM "branded" account has been launched on the Chinese e-commerce platform application Redbook

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest Files Quarterly Financial Statements and MD&A

Solarvest Files Quarterly Financial Statements and MD&A

Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV: SVS) is pleased to announce that its quarterly statements for the period ended October 31, 2021, related management discussion and analysis have been filed and are now available on www.sedar.com.

For the three months ended October 31, 2021 the Company incurred a net loss of $383,510 compared to a net loss of $1,565,335 for the prior year. At October 31, 2021, the Company had $852,237 (July 31, 2021 - $1,388,244) in cash. Working capital at October 31, 2021 was $212,854 (July 31, 2021 - $587,732). Eversea had increased its inventory and inventory work in process over the last quarter to $29,289 finished goods and $199,156 work in process. This is an increase from the July 31 of $6,155 finished goods and $97,204 work in process.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

(TheNewswire)

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Solarvest Files Annual Financial Statements and MD&A

Solarvest Files Annual Financial Statements and MD&A

(TheNewswire)

Solarvest BioEnergy Inc.

TheNewswire - November 19 th 2021 Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV:SVS) is pleased to announce that its audited financial statements for the year ended July 31, 2021, related management discussion and analysis and associated officer's certifications (collectively, the "Annual Filings") have been filed and are now available on www.sedar.com .

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology .

About the Study

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less

Latest Press Releases

Related News

×